Abnova — Investor Presentation 2025

Jul 15, 2025

亞諾法生技股份有限公司 (4133.TW) 2025 年法人說明會

2025/07/17

==> picture [432 x 41] intentionally omitted <==

==> picture [680 x 110] intentionally omitted <==

==> picture [41 x 41] intentionally omitted <==

免責聲明

本簡報及同時發佈之相關訊息包含財務、市場暨產品業務等預測性資訊。 本公司未來實際發生的營運結果及財務狀況可能與這些預測性資訊所明 示或暗示的預估有所差異，其原因可能來自於各種本公司所不能掌控的 風險。這些預估及展望的訊息，反應本公司截至目前為止對於未來的看 法，本公司並不負責隨時提醒或更新。

2

今日議程

亞諾法公司簡介 亞諾法公司介紹與沿革

亞諾法財務報告 2025 Q1 合併損益表與產品別營收分析

亞諾法產品動向 2025年最新產品開發進展

3

亞諾法公司簡介

4

公司介紹與沿革

==> picture [357 x 352] intentionally omitted <==

==> picture [362 x 76] intentionally omitted <==

==> picture [362 x 233] intentionally omitted <==

5

官方網站

==> picture [381 x 469] intentionally omitted <==

==> picture [41 x 41] intentionally omitted <==

6

產品線

==> picture [601 x 323] intentionally omitted <==

==> picture [601 x 69] intentionally omitted <==

==> picture [41 x 41] intentionally omitted <==

7

電子報

==> picture [181 x 371] intentionally omitted <==

==> picture [180 x 295] intentionally omitted <==

==> picture [191 x 346] intentionally omitted <==

==> picture [189 x 347] intentionally omitted <==

==> picture [41 x 41] intentionally omitted <==

8

亞諾法財務報告

9

合併損益表

(新台幣千元) Q1/25	(新台幣千元) Q1/25	% Q4/24	% QoQ Q1/24	% YoY
營業收入	90,498	100% 88,044	100% 3% 85,003	100% 6%
營業成本	50,667	56% 49,651	56% 2% 44,052	52% 15%
營業毛利	39,831	44% 38,393	44% 4% 40,951	48% -3%
營業費用	(33,237)	-37% (34,920)	-40% -5% (29,186)	-34% 14%
營業利益	6,594	7% 3,473	4% 90% 11,765	14% -44%
營業外收入及支出	8,866	10% 15,549	18% 43% 17,279	20% 49%
稅前淨利	15,460 13,605 0.22	17% 19,022 15% 13,490 0.22	22% -19% 29,044 15% 1% 26,704 0% 0.44	34% -47% 31% -49% -50%
稅後淨利
基本每股盈餘(新台幣元)

10

產品別營收分析

==> picture [49 x 22] intentionally omitted <==

==> picture [411 x 264] intentionally omitted <==

==> picture [270 x 235] intentionally omitted <==

11

亞諾法產品動向

12

亞諾法產品動向

體內功能級抗體

NanoAb[TM]

VLP 與 Nanodisc 表達系統膜蛋白

RNAutomation

==> picture [21 x 11] intentionally omitted <==

13

體內功能級抗體

==> picture [773 x 308] intentionally omitted <==

==> picture [41 x 40] intentionally omitted <==

14

NanoAb[TM]

 產品優勢

• 體積小，能增強組織穿透能力。

• 高親和力和卓越的穩定性。

• 低免疫原性，為診斷、治療和多用途研究工具的 理想選擇。

• 可大規模生產，量產過程無需使用到動物。

• 亞諾法已成功開發出+190個奈米抗體，今年度

持續擴增目錄產品。

==> picture [324 x 169] intentionally omitted <==

==> picture [367 x 323] intentionally omitted <==

==> picture [41 x 41] intentionally omitted <==

15

NanoAb[TM]

 NanoAb[TM] conjugated FITC binding affinity assay

Mouse 4-1BB VHH-FITC Mouse CD83 VHH-FITC Human DR5 VHH-FITC Mouse TNFR2 VHH-FITC Clone: 8-2-21 Clone: 121-4-116 Clone: 156-1-100 Clone: 129-18-120 Mouse activated Mouse DC2.4 cell line Human Hela cell line Mouse activated splenocyte-CD8 splenocyte-CD4

 NanoAb[TM] conjugated iFluor 488 binding affinity assay

Human CD79a VHH-iFluor488Human CD34 VHH-iFluor488Mouse FOLR1 VHH-iFluor488Mouse TIM-3 VHH-iFluor488 Clone: 2420 Clone: 5031 Clone: H135 Clone: 4017 Human activated PBMC Human KG-1 cell line Mouse 4T1 cell line Mouse activated splenocyte

 NanoAb[TM] conjugated Aster 647 binding affinity assay

Human PD-L1 VHH-iFluor488 Clone: H140

==> picture [86 x 84] intentionally omitted <==

Human MDA-MB-231 cell line

 BiTE conjugated Dylight650 binding affinity assay

Human nPD-L1 X nCD3e Human nPD-L1 X BiTE-Dylight650 nCD3e BiTE-Dylight650 Human CD8 T cells Human HT29 cell line

==> picture [41 x 41] intentionally omitted <==

16

VLP 與 Nanodisc 表達系統膜蛋白

• 產品優勢

1. VLPs由病毒殼或衣殼蛋白組成，可自我組裝成類 病毒結構，能穩定嵌入膜蛋白而不含病毒基因組 ，適合安全展示膜蛋白結構與功能。

2. VLP系統易於標準化與大量製造，適合膜蛋白研 究與應用透過VLP平台展示膜蛋白可應用於抗體 免疫、疫苗研發、功能篩選與基因治療，且具規 模化生產潛力，方便研究與臨床應用。

3. Nanodisc提供類似細胞膜環境，維持膜蛋白的 天然結構與功能，不需界面活性劑、穩定性高。

4. Nanodisc使膜蛋白可溶於水相，便於純化、分 。

析與藥物篩選

==> picture [336 x 82] intentionally omitted <==

==> picture [390 x 42] intentionally omitted <==

==> picture [83 x 74] intentionally omitted <==

==> picture [81 x 74] intentionally omitted <==

==> picture [79 x 71] intentionally omitted <==

==> picture [87 x 71] intentionally omitted <==

==> picture [71 x 74] intentionally omitted <==

==> picture [87 x 74] intentionally omitted <==

==> picture [79 x 67] intentionally omitted <==

==> picture [78 x 69] intentionally omitted <==

==> picture [41 x 41] intentionally omitted <==

1717

RNAutomation 客製 SAM 、 mRNA, 環狀 RNA 合成與純化的整合型自動化生產服務

==> picture [750 x 361] intentionally omitted <==

==> picture [41 x 41] intentionally omitted <==

1818

RNAutomation mRNA 工作流程

==> picture [575 x 362] intentionally omitted <==

==> picture [41 x 41] intentionally omitted <==

1919

RNAutomation 應用範例㇐

• COVID-19 Omicron Variant mRNA Vaccine for Neutralizing Antibody Production

==> picture [576 x 333] intentionally omitted <==

==> picture [41 x 41] intentionally omitted <==

2020

RNAutomation 應用範例二

• Anti-HER2 Biologic Synthesis by Intravenous mRNA Delivery

==> picture [622 x 317] intentionally omitted <==

==> picture [41 x 41] intentionally omitted <==

2121

RNAutomation 應用範例二

• Anti-HER2 Biologic Synthesis by Intravenous mRNA Delivery

==> picture [41 x 41] intentionally omitted <==

2222

THANK YOU   Innovate Transform Grow

==> picture [140 x 37] intentionally omitted <==

Innovate through Integrated Solutions www.abnova.com.tw

==> picture [147 x 137] intentionally omitted <==

==> picture [147 x 137] intentionally omitted <==

==> picture [146 x 69] intentionally omitted <==

==> picture [169 x 83] intentionally omitted <==

==> picture [146 x 69] intentionally omitted <==

==> picture [40 x 39] intentionally omitted <==